Literature DB >> 14975696

Neuroprotective role of phosphodiesterase inhibitor ibudilast on neuronal cell death induced by activated microglia.

Tetsuya Mizuno1, Tohru Kurotani, Yukio Komatsu, Jun Kawanokuchi, Hideki Kato, Norimasa Mitsuma, Akio Suzumura.   

Abstract

The phosphodiesterase inhibitor, ibudilast, has many effects on lymphocytes, endothelial cells, and glial cells. We examined the neuroprotective role of ibudilast in neuron and microglia co-cultures. Ibudilast significantly suppressed neuronal cell death induced by the activation of microglia with lipopolysaccharide (LPS) and interferon (IFN)-gamma. To examine the mechanisms by which ibudilast exerts a neuroprotective role against the activation of microglia, we examined the production of inflammatory and anti-inflammatory mediators and trophic factors following ibudilast treatment. In a dose-dependent manner, ibudilast suppressed the production of nitric oxide (NO), reactive oxygen species, interleukin (IL)-1beta, IL-6, and tumor necrosis factor (TNF)-alpha and enhanced the production of the inhibitory cytokine, IL-10, and additional neurotrophic factors, including nerve growth factor (NGF), glia-derived neurotrophic factor (GDNF), and neurotrophin (NT)-4 in activated microglia. Thus, ibudilast-mediated neuroprotection was primarily due to the inhibition of inflammatory mediators and the upregulation of neurotrophic factor. In the CA1 region of hippocampal slices, long-term potentiation (LTP) induced by high frequency stimulation (HFS) could be inhibited with LPS and interferon-gamma stimulation. Ibudilast returned this LTP inhibition to the levels observed in controls. These results suggest that ibudilast may be a useful neuroprotective and anti-dementia agent counteracting neurotoxicity in activated microglia.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14975696     DOI: 10.1016/j.neuropharm.2003.09.009

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  71 in total

1.  Allosteric inhibition of macrophage migration inhibitory factor revealed by ibudilast.

Authors:  Yoonsang Cho; Gregg V Crichlow; Jon J Vermeire; Lin Leng; Xin Du; Michael E Hodsdon; Richard Bucala; Michael Cappello; Matt Gross; Federico Gaeta; Kirk Johnson; Elias J Lolis
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-08       Impact factor: 11.205

Review 2.  The discovery and development of analgesics: new mechanisms, new modalities.

Authors:  Gillian Burgess; Dic Williams
Journal:  J Clin Invest       Date:  2010-11-01       Impact factor: 14.808

3.  The glial cell modulators, ibudilast and its amino analog, AV1013, attenuate methamphetamine locomotor activity and its sensitization in mice.

Authors:  Sarah E Snider; Sarah A Vunck; Edwin J C G van den Oord; Daniel E Adkins; Joseph L McClay; Patrick M Beardsley
Journal:  Eur J Pharmacol       Date:  2012-01-28       Impact factor: 4.432

4.  Fractalkine attenuates excito-neurotoxicity via microglial clearance of damaged neurons and antioxidant enzyme heme oxygenase-1 expression.

Authors:  Mariko Noda; Yukiko Doi; Jianfeng Liang; Jun Kawanokuchi; Yoshifumi Sonobe; Hideyuki Takeuchi; Tetsuya Mizuno; Akio Suzumura
Journal:  J Biol Chem       Date:  2010-11-11       Impact factor: 5.157

Review 5.  Methamphetamine addiction: involvement of CREB and neuroinflammatory signaling pathways.

Authors:  Irina N Krasnova; Zuzana Justinova; Jean Lud Cadet
Journal:  Psychopharmacology (Berl)       Date:  2016-02-12       Impact factor: 4.530

Review 6.  Discovering cytokines as targets for chemotherapy-induced painful peripheral neuropathy.

Authors:  Xiao-Min Wang; Tanya J Lehky; Joanna M Brell; Susan G Dorsey
Journal:  Cytokine       Date:  2012-04-24       Impact factor: 3.861

Review 7.  Drug repositioning: playing dirty to kill pain.

Authors:  Leandro Francisco Silva Bastos; Márcio Matos Coelho
Journal:  CNS Drugs       Date:  2014-01       Impact factor: 5.749

Review 8.  Recent Advances in Pharmacotherapy for Migraine Prevention: From Pathophysiology to New Drugs.

Authors:  Jonathan Jia Yuan Ong; Diana Yi-Ting Wei; Peter J Goadsby
Journal:  Drugs       Date:  2018-03       Impact factor: 9.546

9.  Reversal of established traumatic brain injury-induced, anxiety-like behavior in rats after delayed, post-injury neuroimmune suppression.

Authors:  Krista M Rodgers; Yuetiva K Deming; Florencia M Bercum; Serhiy Y Chumachenko; Julie L Wieseler; Kirk W Johnson; Linda R Watkins; Daniel S Barth
Journal:  J Neurotrauma       Date:  2013-11-20       Impact factor: 5.269

10.  Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis.

Authors:  Robert J Fox; Christopher S Coffey; Merit E Cudkowicz; Trevis Gleason; Andrew Goodman; Eric C Klawiter; Kazuko Matsuda; Michelle McGovern; Robin Conwit; Robert Naismith; Akshata Ashokkumar; Robert Bermel; Dixie Ecklund; Maxine Koepp; Jeffrey Long; Sneha Natarajan; Srividya Ramachandran; Thomai Skaramagas; Brenda Thornell; Jon Yankey; Mark Agius; Khurram Bashir; Bruce Cohen; Patricia Coyle; Silvia Delgado; Dana Dewitt; Angela Flores; Barbara Giesser; Myla Goldman; Burk Jubelt; Neil Lava; Sharon Lynch; Augusto Miravalle; Harold Moses; Daniel Ontaneda; Jai Perumal; Michael Racke; Pavle Repovic; Claire Riley; Christopher Severson; Shlomo Shinnar; Valerie Suski; Bianca Weinstock-Gutman; Vijayshree Yadav; Aram Zabeti
Journal:  Contemp Clin Trials       Date:  2016-08-10       Impact factor: 2.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.